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Abstract: 
The epithelial-mesenchymal transition (EMT) is one of  the crucial procedures for cancer 
invasion and distal metastasis. Despite undergoing intensive studies, the mechanisms 
underlying EMT remain to be completely elucidated. Here, we identified that 
apoptosis-stimulating protein of  p53-2 (ASPP2) is a novel target of  MiR-205 in various 
cancers. Interestingly, the binding site of  MiR-205 at the 3’-UTR region of  ASPP2 was 
highly conserved among different species. An inverse correlation between MiR-205 and 
ASPP2 was further observed in vivo in cervical cancers, suggesting MiR-205 may be an 
important physiological inhibitor of  ASPP2. Hypoxia is a hallmark of  solid tumor 
microenvironment and one of  such conditions to induce EMT. Notably, MiR-205 was 
remarkably induced by hypoxia in cervical and lung cancer cells. A dramatic suppression 
of  ASPP2 was observed simultaneously. Further studies confirmed that hypoxia-induced 
ASPP2 suppression was mainly attributed to the elevated MiR-205. Interestingly, the 
alteration of  MiR-205/ASPP2 under hypoxia was accompanied with the decreased 
epithelial marker E-cadherin and increased mesenchymal marker Vimentin as well as a 
morphological transition from the typical cobblestone-like appearance to the 
mesenchymal-like structure. More importantly, MiR-205 mimics or ASPP2 silencing 
similarly promoted EMT process. By contrast, ASPP2 recovery or MiR-205 inhibitor 
reversed MiR-205-dependent EMT. Further studies demonstrated that the newly revealed 
MiR-205/ASPP2 axis promoted cell migration and also increased cell proliferation both 
in vivo and in vitro. These data together implicated a critical impact of  MiR-205/ASPP2 
on promoting EMT. MiR-205/ASPP2 may be potential diagnostic and therapeutic 
biomarkers in cervical and lung cancers. 
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The epithelial-mesenchymal transition (EMT) was initially identified as a fundamental 
tissue remodeling mechanism of  embryonic development1. More recently, mounting 
evidence has suggested that EMT is also one of  critical procedures for cancer metastasis2, 
3, 4, 5. Given that more than 90% of  cancer related mortality is due to cancer metastasis, 
dissecting the precise mechanisms of  EMT will facilitate the discovery of  novel 
diagnostic and therapeutic biomarkers and ultimately improve cancer prognosis in 
general.  
Cells undergoing EMT are featured by the loss of  cell-cell adhesion and the 
acquirement of  a mesenchymal phenotype, which is accompanied by the typical 
molecular changes, such as the loss of  epithelial marker E-cadherin and the gain of  
mesenchymal markers Vimentin 6. As such, in the process of  EMT, epithelial cells will go 
through fundamental morphological changes from typical cobblestone-like structure to 
spindle-shaped phenotype with increased cell motilities7. Mechanistically, EMT can be 
regulated at different levels. The activation of  transcriptional factors, such as HIF-1a, 
snail, twist, slug and β-catenin, can modulate EMT process by stimulation or repression 
panels of  EMT-related target genes 8, 9. Recently, Micro-RNAs (MiRNAs) have also been 
proved to modulate EMT progress at epigenetic levels 10, 11. MiRNAs is found to be 
endogenously expressed small non-coding RNA gene products of  approximately 22 
nucleotides that down-regulate gene expression by binding to the 3’untranslated regions 
(3’UTR) of  specific target messenger RNAs (mRNAs), leading to mRNA degradation or 
inhibition of  translation12. Despite being discovered not long time ago, MiRNAs’ 
importance in controlling gene transcriptome has gained great attention. It is thus not 
surprising to know that MiRNAs are important component of  EMT machineries. For 
instance, loss of  MiR-200 family or MiR-205 are association with cancer metastasis 13, 14, 15. 
This, at least in part, attributes to its inhibitory activity towards EMT by targeting 
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transcriptional repressors of  E-cadherin , ZEB1 and ZEB2 14, 16, 17. However, MiRNAs can 
target various genes and single gene can be modulated by many MiRNAs, therefore, the 
biological outcomes of  MiRNA activation may change with cell content and stimulus, 
which provides potential explanations for the complicated and even controversial 
functions of  MiRNA. MiR-205 is such a “double-edged sword” in cancer. Whereas it was 
initially considered as a tumor suppressor and the majority of  its targets reported so far 
are oncogenes 18, recently, its pro-proliferation and pro-metastatic oncogene functions 
have also been discovered 19, 20, 21, 22. However, the underlying mechanisms of  this 
oncogenetic function, particularly in regulating EMT, remain to be elucidated. 
ASPP2 belongs to the apoptosis stimulating proteins of  p53 (ASPP) family, which 
directly interacts with p53 family members and selectively promotes their transcriptional 
activities toward pro-apoptosis genes 23, 24. Further evidences from mice model revealed 
that ASPP2 is a haploinsufficient tumor suppressor 25. Indeed, ASPP2 expression is 
deregulated in several human tumor types, and ASPP2 suppression is associated with 
more aggressive phenotypes and poor clinical outcomes of  cancers 26, 27, 28, 29. Recently, 
emerging evidence has suggested that ASPP2’s functions do not always rely on p53. Mak 
VC et al found that ASPP2 can inhibit cell migration through modulating Src tyrosine 
kinase activities 27. Additionally, ASPP2 has been reported to form complex with tight 
junction competent par-3 and regulates cell polarity of  neoepithelial cells in a 
p53-independnet manner 30, 31, 32. Moreover, it has been recently found that ASPP2 can 
inhibit EMT by preventing the activation of  Wnt signaling in cancers 33. These data 
provide important molecular explanations for the clinical significance of  ASPP2 in 
cancer metastasis. Nevertheless, compared with the biological functions of  ASPP2, much 
less is known about its regulatory mechanisms on gene expression. Underlying 
mechanisms of  ASPP2 regulated by MiRNAs and the resulting biological impacts of  
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such regulation on EMT remains largely unknown.  
In this study, our results showed here that ASPP2 is a representative tumor 
suppressor target of  MiR205 in multiple cancers. The inverse correlation between ASPP2 
and MiR-205 was further revealed in vivo in human cervical specimens. Notably, hypoxia 
is one of  the hallmarks of  solid tumor microenvironment and also one of  such conditions 
to induce EMT. The newly identified MiR-205/ASPP2 axis was induced by hypoxia 
exposure and played crucial roles in regulating hypoxia-induced EMT via influencing 
E-cadherin and Vimentin. Further studies showed that MiR-205/ASPP2 axis contributes 
to such biological outcomes as the promoted migration and cell survival. 
Results 
MiR-205 is negatively associated with ASPP2 both in vitro and in vivo. In order to 
understand the underlying epigenetic regulation of  ASPP2 by miRNAs, the potential 
miRNA binding sites located at 3’-UTR regions of  ASPP2 were predicted by the 
commonly cited bioinformatic tools such as microRNA.org, TargetScan4, miRBase, 
PicTar and miRanda. Five targets (MiR-205, 221, 222, 144 and 139) were predicted by at 
least four of  above databases (Supplementary Figure S1a). To validate the bioinformatic 
results, these miRNA mimics were overexpressed respectively in 293T cells, and both 
mRNA and protein levels of  ASPP2 were examined subsequently. MiR-221, 222, 144, 
and 139 showed no obvious impact on ASPP2’s expression at either mRNA or protein 
level (Supplementary Figure S1b). However, upon MiR-205 mimics treatment, ASPP2 
expression was significantly repressed up to 44.9% at mRNA level and up to 35.0% at 
protein level (P<0.01, Supplementary Figure S1b). In addition, the regulation of  ASPP2 
                                                                                                  6 
by MiR-205 is likely a common event, because similar results were obtained in the 
cervical (Hela and SiHa), lung (A549) and renal (RC-1) cancer cells (Figure 1a and 
Supplementary Figure S1c, S2). In support of  this, MiR-205 inhibitor promoted ASPP2’s 
expression at both mRNA levels and protein levels in all cell models involved (Figure 1b 
and Supplementary Figure S1c). More impotently, the regulation of  ASPP2 by MiR-205 
likely also occurs in vivo. As shown in Figure 1c, ASPP2 was decreased and MiR-205 was 
increased in cervical cancers in compared with paired normal controls. Furthermore, the 
levels of  ASPP2 and MiR-205 were inversely correlated with each other, suggesting 
MiR-205-mediated gene silencing may be one of  major mechanisms to inhibit ASPP2 in 
vivo at least in cervical cancers (r2=0.55, P<0.01, Figure 1d). 
ASPP2 is a direct target of MiR-205. According to the bioinformatics analysis, there is 
one single potential binding sites of  MiR-205 at ASPP2 3’-UTR. The complementarity of  
ASPP2 3’-UTR with the seed sequence of  MiR-205 were shown in Figure 1e. 
Interestingly, the MiR-205 binding site in ASPP2 was conserved among different species 
(Figure 1f), suggesting that the regulation might play important roles in modulating 
fundamental functions of  ASPP2. We then constructed luciferase reporter containing 
whole ASPP2 3’-UTR (WT, 961bp) (Figure 1e), which was co-transfected with the 
Renilla luciferase reporter plasmid into cells. Remarkably, ASPP2 3’-UTR (WT) 
luciferase signals were reduced by 50-60% in response to MiR-205 expression in 
comparison with cells transfected with the same amount of  scramble control in 293T 
(56.0%, P<0.05), Hela (50.5%, P< 0.01), SiHa (75.4%, P< 0.01), and A549 (41.3%, P< 
0.01) cells (Figure 1g). To further confirm the reduced luciferase signal is due to a direct 
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interaction of  MiR-205 and the putative sites at ASPP2 3’UTR, a MiR-205 binding sites 
mutated 3’-UTR luciferase reporter, ASPP2 3’-UTR (MT), were generated by 
mutagenesis kits (Figure 1e). As expected, MiR-205 failed to affect the luciferase signals 
of  ASPP2 3’-UTR (MT) under the same conditions (Figure 1g). These data together 
suggests that ASPP2 indeed is a direct target of  MiR-205. 
ASPP2 is subject to the regulation of hypoxia and confers hypoxia-induced EMT. 
Hypoxia is a key microenviromental factor to promote cancer metastasis. As a newly 
identified tumor suppressor, ASPP2 deregulation has been associated with advanced 
cancers. We therefore asked whether ASPP2 is subjected to the regulation of  hypoxia. As 
reported previously, we found that HIF-1a was dramatically increased with hypoxia 
(2.0% O2) treatment (top panel, Figure 2a). The mRNA levels of  its well-known 
transcriptional target VEGF were also correspondingly increased (Supplementary Figure 
S3). Under such conditions, ASPP2 was remarkably and consistently decreased at mRNA 
levels to different extends in cervical (Hela and SiHa) and lung (A549) cancers (P<0.05, 
Figure 2b). In addition, an obvious suppression of  ASPP2 protein was also confirmed by 
both Western blotting and immunofluorescence assay as shown in Figure 2a and c, 
respectively.  
Interestingly, ASPP2 was found to locate mainly at cell-cell junction, where it 
colocalized with E-cadherin under the normoxia conditions (Figure 2c). Upon hypoxia 
switch, ASPP2 suppression was paralleled with the inhibition of  epithelial marker 
E-cadherin and the induction of  mesencymal marker Vimentin (Figure 2a and c, 
Supplementary Figure S4), suggesting cells were undergoing EMT process. In support of  
it, cells cultured under the hypoxia condition lost typical epithelial cobblestone like 
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structure and showed as a more elongated spindle-shaped morphology (Figure 2c). 
Importantly, when ASPP2 expression was arbitrarily resumed by introducing ASPP2 
constructs, the decreased E-cadherin and increased Vimentin were largely restored 
(Figure 2d and 2e). In addition, an obvious junctional recruitment of E-cadherin and 
ASPP2 were observed particularly between two adjacent cells both with exogenous 
ASPP2 expression under hypoxia conditions (Figure 2e). These data together pointed to 
the notion that ASPP2 prevents hypoxia-induced EMT and this ability of  ASPP2 may be 
dependent on its precise junctional localization.  
Enhanced MiR-205 promotes EMT via targeting ASPP2 under hypoxia conditions. We 
then asked whether MiR-205 is involved in ASPP2 inhibition under hypoxia conditions. 
First of  all, the expression of  MiR-205 was compared between cells cultured under the 
normoxia and hypoxia conditions. Remarkably, MiR-205 was increased in various cells 
under hypoxia conditions (44.4%, P<0.05 in Hela cells; 47.7%, P<0.05 in SiHa cells and 
13.0% P<0.01 in A549 cells, Figure 3a). Interestingly, MiR-205 induction was linearly 
correlated with ASPP2 suppression (r2=0.9932, P<0.01, Figure 3b). In addition, 
accumulation of HIF-1a is the most critical adaptive response to hypoxia. Ectopic 
expression of HIF-1a promoted MiR-205 expression by 5.7-folds in HeLa and 2.2 folds 
in SiHa cells (P<0.01, Figure 3c and e), suggesting that hypoxia-induced MiR-205 
expression is largely dependent on HIF-1a. Supportively, preventing HIF-1a 
accumulation by RNAi-mediated HIF-1a knocking down under hypoxia conditions 
resulted in a significant suppression of MiR-205 expression (P<0.01, Figure 3d and f). 
Importantly, both mRNA and proteins of ASPP2 exhibited a negative association 
with MiR-205 upon genetic modulation of HIF-1a (P<0.01, Figure 3g and h). These 
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data together suggested that ASPP2 is subjected to MiR-205 regulation under hypoxia 
conditions. In support of  this, ASPP2 was significantly suppressed by MiR-205 mimics 
(Figure 3i and top panels, 4j, supplementary Figure S5). By contrast, MiR-205 inhibitor 
efficiently repressed hypoxia-induced MiR-205 by more than 50%, as confirmed by a 
real-time RT-PCR assay (Figure 3k). ASPP2 was correspondingly restored by the same 
treatment (Top panels, Figure 3l). Therefore, MiR-205 is one of  critical physiological 
regulator of  ASPP2 under hypoxia conditions.  
Next, the role of  MiR-205 in regulating EMT was investigated. Firstly, the elevation of  
MiR-205 was parallel with E-cadherin suppression and Vimentin induction with hypoxia 
switch (Figure 2a and 3a, supplementary Figure S5). In addition, arbitrarily introducing 
MiR-205 mimic under normoxia conditions led to E-cadherin suppression and Vimentin 
induction (Figure 3i and middle panels, 3j). Meanwhile, cells lost the typical epithelial 
morphology and exhibited an elongated fibroblast-like phenotype (Figure 3i). Conversely, 
decreased E-cadherin and increased Vimentin were both rescued upon MiR-205 inhibitor 
treatment under hypoxia conditions (middle panels, Figure 3l). These data implicated 
that MiR-205, like its target ASPP2, participates in hypoxia-induced EMT process, and 
behave as an EMT promoter, which is opposite to the biological outcomes generated by 
ASPP2. 
We further examined the contribution of  ASPP2 in MiR-205-dependent EMT by 
ASPP2 rescue experiment. Remarkably, the ability of  MiR-205 in regulating EMT as 
presented by E-cadherin suppression and Vimentin induction was largely abrogated by 
arbitrary expression of  ASPP2 (Figure 3j). Taken these data together, MiR-205/ASPP2 
axis is critical in hypoxia induced EMT. 
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MiR-205/ASPP2 axis promotes cell migration. Cells undergoing EMT generally 
exhibits elevated cell motility; therefore, we further examined the impact of  
MiR-205/ASPP2 axis on cell migration. ASPP2 was suppressed by RNAi (Si-ASPP2), 
which specifically targets ASPP2 mRNA degradation. ASPP2 was consistently decreased 
up to 60-90% as shown in Figure 4a in multiple cell lines, compared with the scramble 
controls (P<0.01). Cell motility was then evaluated by a wound healing assay in cells with 
or without ASPP2 silencing. As shown in Figure 4b and c, inhibiting ASPP2 significantly 
increased cell migration rates. The difference became significant 24 hours after making 
the wound and turned more evident over time (P<0.05, Figure 4b and c). The migration 
alternation was further confirmed by transwell assays (Figure 4d and e). Similarly, cells 
with ASPP2 silencing migrate more efficiently through the micropore wells than the cells 
treated with scramble controls. The increased migration rate ranged from 2 to 3 folds in a 
cell type-dependent manner (P<0.05, Figure 4d and e). 
The ability of  MiR-205 in regulating cell migration was also examined in the same set 
of  cell models. MiR-205 overexpression inhibited ASPP2 expression (Figure 5a). Similar 
to ASPP2 silencing, these cells with MiR-205 overexpression exhibited an increased 
migration rate revealed by both wound healing assays and transwell assays (Figure 5b-e). 
Remarkably, re-expression of  ASPP2 prevented the enhanced cell migration induced by 
MiR-205(Figure 5b-e), suggesting ASPP2 is one of  major targets of  MiR-205 that confers 
to MiR-205-promoted cell migration. 
MiR-205/ASPP2 axis promotes cell growth both in vitro and in vivo. Since cell-cell 
contact disruption can also promote cell proliferation, we further asked whether 
MiR-205/ASPP2 also affect cell proliferation. The survival rates of  cervical and lung 
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cancer cells were significantly enhanced in ASPP2 silenced cells. This increased 
proliferation appeared at 24 hours in SiHa and A549 cells, and at 48 hours in Hela cells, 
which turned more obvious over time. Statistic significance were obtained at 72 hours 
cultures in all three cells studied (P<0.05, Figure 6a). By contrast, MiR-205 influenced 
cell proliferation in an opposite way from ASPP2, which markedly promoted cell 
proliferation (P<0.05, Figure 6b). Conversely, MiR-205 inhibitor significantly 
suppressed MiR-205 expression under hypoxia conditions and simultaneously 
inhibited cell proliferation rates in both HeLa and SiHa cells (P<0.05, Supplementary 
Figure S6). Importantly, recovery ASPP2 expression successfully inhibited the MiR-205 
mediated cell growth (Figure 6b). These data suggested that ASPP2 is an important 
downstream target of  MiR-205 to promote cell proliferation.  
The influence of  MiR-205/ASPP2 on cell survival was further confirmed in vivo by 
using xenograft mice models. SiHa cells stably expressing DsRed control or 
DsRed+MiR-205 by lenti virus expression system were injected subcutaneously in nude 
mice. To minimize the potential variation generated by the nature of  individual nude 
mice, the same number of  SiHa/DsRed control and SiHa/DsRed+MiR-205 cells were 
paired and injected into one nude mouse at symmetrical subcutaneous regions, 
respectively (Figure 6c). The DsRed fluorescence signal was monitored by the in vivo 
imagining system weekly. The tumor burden became evident in both SiHa sublines two 
weeks after injection. Since then, MiR-205 overexpression xenograft showed a more 
dramatically increased growth rate than the control. The difference in tumor size between 
the two groups became statistic significant 3 weeks after injection (P<0.05) and turned 
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more evident over time (P<0.01, Figure 6c). At the end of  experiments, the mice were 
dissected, and the tumor weight was measured immediately. As shown in Figure 6d, the 
tumor weight was significantly increased with MiR-205 overexpression cells (P<0.01, 
Figure 6d). The overxpression of  MiR-205 was confirmed in the dissected xenograft. The 
down regulation of  ASPP2 was also confirmed at mRNA levels by real-time RT-PCR 
(P<0.01, Figure 6e) and at protein levels by western blotting (Figure 6f). Furthermore, the 
decreased E-cadherin and increased Vimenin were correspondingly observed in the 
representative samples of  SiHa-DsRed+MiR-205 cells as shown in the Figure 6f. These 
data together suggest that, consistent with the in vitro data described above, 
MiR-205/ASPP2 axis promotes cell growth in vivo. 
Discussion 
Here we identified that ASPP2 is novel tumor suppressor target of  MiR-205 and plays 
key roles in mediating MiR-205-induced EMT, which provides important molecular 
explanations for the not yet well-defined oncogenic functions of  MiR-205, particularly in 
promoting invasion and metastasis. Furthermore, we also found that the newly identified 
MiR-205/ASPP2 axis can be modulated by microenviromental hypoxia, implicating a 
critical impact of  MiR-205/ASPP2 on promoting cancer progress in the hypoxia niche of  
solid tumors (Figure 7). 
Down-regulation of  MiR-205 has been observed in a panel of  cancers, such as breast, 
prostate, bladder and gliomas and head and neck, pointing to a tumor suppressor activity 
of  MiR-20514, 34, 35, 36, 37, 38. Indeed, most of  its targets identified so far are oncogenes (e.g., 
ErbB3, VEGF-A, ZEB1/2, ZEB1/2, ΔNp63α, SFK and PKCε)18. Simultaneously, 
however, evidence for an oncogenic role of  MiR-205 also began to accumulate. For 
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example, Xu et al found that MiR-205 confers to the elevated radiation resistance of  
human nasopharyngeal carcinoma by targeting PTEN 20. The MiR-205/PTEN axis has 
later been reported also to promote cell growth in lung and endometrial cancer 19, 39, 40. In 
addition, overexpression of  MiR-205 is associated with the suppression of  another two 
targets, CYR61 and CTGF, in cervical cancers and SHIP-2 in squamous cell carcinoma21, 
41.More recently, MiR-205 was also reported to promote cell migration and invasion in 
normal keratinocytes, ovarian and cervical cancer cells 21, 22, 42, which is in support of  our 
results obtained in this study. Moreover, we further identified that this oncogenic 
capability of  MiR-205 is possibly attributed to its activity in promoting EMT. This result 
seems controversial with the well established concept that MiR-205 expression inhibits, 
rather than promotes, EMT program by targeting ZEB1/2, leading to an increased 
E-cadherin in breast, bladder and prostate cancers 14, 43, 44. Nevertheless, despite detailed 
mechanisms remain unknown, Li et al reported that MiR-205 expression is associated 
with the E-cadherin suppression during the development of  extra embryonic endoderm 45, 
which is in consistent with our results. So, our data together with others suggested that 
MiR-205 may have a double-edged sword effect on EMT. One potential explanation is 
that MicroRNAs can target multiple genes, therefore, the biological outcomes of 
MiRNA activation may change with cell content and stimulus. Jia Yu et al proposed 
that MiR-184 can interfere with the binding between MiR-205 and its target SHIP2 
mRNA41. We can not exclude the possibility that other similar microRNAs also exist 
in cervical and lung cancer cells, which may be involved in the regulation of the 
selectivity of MiR-205 in binding with its potential targets. An alternative explanation 
is that MicroRNA fulfill its task via binding with 3’-UTR region of target mRNA. 
However, the expression of tumor suppressor can be regulated by numbers mechanisms, 
such as gene deletion or epigenetic promoter methylation and histone modification. So, 
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if those tumor suppressor targets of MiR-205, such as ASPP246, are suppressed by the 
above mentioned mechanisms, no targeting mRNA will be available for MiR-205 to 
bind. Instead, MiR-205 may selectively regulate its oncogene target, such as Zeb1, 
which is normally highly expressed in cancers and thus lead to promoted EMT in 
malignancies, such as breast cancers.  
In contrast to the anti-EMT mechanism of  MiR-205, the exact mechanisms underlying 
the pro-EMT activities of  MiR-205 remain largely unknown. Here, we found that ASPP2 
is a direct target of  MiR-205. The inverse association between ASPP2 and MiR-205 is not 
only validated by transfection with either MiR-205 mimic or inhibitors, and also observed 
in cervical tissues. Importantly, ASPP2 suppression produces a similar biological 
outcome to MiR-205 in regulating EMT. Critically, arbitrary expression of  ASPP2 can 
prevent MiR-205-induced EMT. These data together suggest that ASPP2 is a key target of  
MiR-205 to promote EMT.  
Initially identified as a p53 activator, ASPP2 has been recently found to form complex 
with tight junction component Par-3 and thus plays important roles in maintaining 
epithelial polarity 30, 31. Interestingly, tight junctional components are important targets for 
MiRNA-regulated EMT progress, as demonstrated in a microarray experiment47. This is 
also in keep with another report by Chung et al. that there are 11 tight junction proteins 
among 24 significant validated targets of  MiR-205 in mammalian bladder urothelial 
cells48. These data are in support of  our findings that ASPP2 is a key target of  MiR-205 in 
regulating EMT. Wang et al provided solid evidence that ASPP2 inhibits EMT by 
stabilization of  β-catenin-E-cadherin complex at cell-cell junctions and subsequent 
inhibition of  Wnt signaling transduction pathway 33. Here we found that ASPP2 is 
mainly localized at cell-cell junctions. MiR-205 suppresses ASPP2 by inhibiting its 
transcription and protein expression and thus depleted its function at junction.  
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It is also worth of  note that hypoxia is a hallmark of  solid cancer49. Cancer cells gain 
the capability to adapt to hypoxia via modulating gene expression patterns by utilizing 
different strategies50. Hypoxia induces upregulation of  MiR-205 and subsequent 
inhibition of  ASPP2, resulting in EMT, migration and proliferation, which is thus an 
adaptative and protective response to hypoxia. The newly identified pro-EMT activity 
of MiR-205 indicated that MiR-205 inhibitor may be potentially used to treat cervical 
cancer and lung cancer and counteract with hypoxia-induced malignant growth. It 
will be of interesting to further test this hypothesis in vivo by generating 
well-controlled hypoxic xenografts. It is also worth noting that MiR-205 has been 
reported to be suppressed under hypoxia conditions in prostate cancer and renal cell 
carcinoma cells51,52. These reports together with ours support previous idea raised by 
Camps, C. et al. By a genome wild study, they found that microRNA expression can 
be regulated by hypoxia in a tissue specific manner53. This may be due to the complex 
regulatory machineries of microRNAs. The underlying mechanisms of 
hypoxia-regulated MiR-205 expression warrant further examination. 
To our knowledge, despites MiRNAs have been widely accepted as an important 
regulator of  gene expression, their roles in regulating ASPP2 remains unknown. For the 
first time, we provided important information on the epigenetic regulation of  ASPP2 by 
MicroRNAs, MiR-205. Of  note is that dysfunction of  ASPP2 under hypoxia condition 
may be fulfilled by various mechanisms in addition to MiR-205-meidated ASPP2 
silencing. For example, Kim et al recently found that ASPP2 can be inhibited by 
Siah2-induced proteasome degradation under hypoxia conditions 54.  
Taken together, Hypoxia/MiR-205/ASPP2/EMT is a newly identified mechanism for 
cancer progression. Inhibiting MiR-205 or rescue ASPP2 are potential therapeutic 
strategies to inhibit the metastasis of  cervical and lung cancers.  
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Materials and Methods  
Tissue samples. Samples of  6 cervical cancer and the paired normal controls were 
obtained from the first affiliated hospital, Harbin Medical University. All samples were 
obtained with approval from the Institutional Ethics Committee. 
Cell lines and culture conditions. The human cervical cancer cell lines (Hela and SiHa) 
and human lung cancer cell line A549 were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). The cells were cultured in DMEM medium 
supplemented with 10％ fetal bovine serum (FBS). Cells were incubated at 37 ℃ 
incubator in an atmosphere of  5％ CO2. For hypoxia treatment, cells were cultured in an 
atmosphere of  2％ O2，5％ CO2 at 37℃ in a hypoxia incubator for the indicated period 
of  time. All cell lines were authenticated and characterized by the supplier. The cells were 
expanded immediately and multiple aliquots were cryopreserved. All cell lines have never 
been passaged longer than 3 months and the cell lines were characterized by Genetic 
Testing Biotechnology Corporation (Suzhou, China) using short tandem repeat (STR) 
markers.  
RNA extraction and quantitative RT-PCR. Total RNA was isolated from cells with 
Trizol (Invitrogen,USA) following the manufacturer’s protocol. 1μg total RNA was 
reverse transcribed using a PrimeScript reverse transcription (RT) reagent kit in the 
presence of  gDNA Eraser. cDNA synthesis was suggested by the kit protocol. Reverse 
transcription was performed for 15 minutes (min) at 37℃，85℃ for 5 second (sec), and 
finally at 4℃  forever. After the RT reaction, the cDNA was diluted 10-fold and 
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performed the quantitative RT-PCR using SYBR Premix Ex Tag II. The conditions were 
as follows: 95℃ for 30 sec, 40 cycles of  95℃ for 5 sec, 58℃ for 34 sec and last stage at 
95℃ for 15 sec, 60℃ for 1 min, 95℃ for 15 sec by using an applied Biosystems 7500 
real-time PCR system. mRNA levels were calculated according to the Ct value. The 
housekeeping gene GAPDH was used as an internal control. The primer sequences used 
in this study are listed below: ASPP2 Forward 5’-GAAGACTCGGTGAGCATGCG-3’ 
Reverse 5’-GCGATACGCTCTGAGCCAGT -3’; VEGF Forward 5’-GAAT 
CATCACGAAGTGGTGAAGT -3’ Reverse 5’-GTTG GACTCCTCAGTGGGC -3’ and 
GAPDH Forward 5’-CGACCACTTTGTCAAG CTCA-3’ Reverse 5’-ACTGAGT 
GTGGCAGGGACTC-3’ 
Western Blot. Proteins were extracted from cells using urea buffer (2M Thiourea, 4％
CHAPS, 40mM Tris-Base, 40mM DTT, 2％Pharmalyte ). Equal amount of proteins 
were separated at sodium dodecyl sulfate-polycylamide gel electrophoresis (SDS-PAGE), 
and then transferred to PVDF membranes using the cold transfer buffer. Membranes 
were blocked with 5％ non-fat milk in TBS-T for 1 hour at room temperature, and 
subjected to corresponding primary antibody at 4℃over night. Antibodies used were list 
as bellow: ASPP2 (Sigma-Aidrich, 1:2000), β-actin (Sigma-Aidrich, 1:2000), HIF-1α 
（Abcam, 1:750）, Vimentin (Santa Cruz, 1:2000), E-cadherin (Santa Cruz,1:2000) and 
GAPDH (Sigma-Aidrich, 1:2000). Secondary antibodies, goat anti-mouse-HRP and goat 
anti-rabbit-HRP, were diluted at 1:2000. Signals were visualized by ECL. Membrane was 
then ready for scanning by Image studio system (ECL, LI-COR, USA). Protein 
quantification was conducted by image J software. The gray values of protein were 
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achieved as gray level of protein band/gray level of loading control. 
MTT. Cell proliferation was detected by the colorimetric MTT assay. The cell lines were 
plated in 96-well plates. After 0h, 24h, 48h and 72h incubation, cells were treated with 
MTT solution at the concentration of 5 mg/mL for 4h at 37℃. The MTT was discarded 
and formazan was dissolved with 100 μL DMSO. Finally, the absorbance at 490 nm was 
determined using Microplate Reader (Tecan Austria GmbH 5082, Austria) 
Luciferase assay. The 3’-UTR sequence of ASPP2 was amplified from genomic DNA 
derived from HEK293 cells by PCR. The PCR product was then inserted into 
pMIR-REPORT vector (Applied Biosystems). According to the binding sites of  MiR-205 
on 3’-UTR region of  ASPP2, the mutant (MUT) pMIR-ASPP2-Report was generated by 
using mutagenesis kit according to the manufacture’s introduction using wild type (WT) 
pMIR-ASPP2-Report as a template (Stratagene). The cells were seeded into 24-well plates 
by 3×104 cells/ well and then transfected with a mixture of  15ng pRL-TK Renilla 
luciferase, 40pmol MiR-205 mimic or negative control and 300ng WT or MUT 
pMIR-ASPP2-Report using Lipofetamine 2000 (invitrogen). After 48h, the cells were 
harvested and subjected to a assay by using the Dual Luciferase Reporter Assay system 
(Promega, Madison, USA). The relative luciferase activities were normalized with the 
Renilla luciferase activities. 
MicroRNAs isolation and Taqman Quantitative RT-PCR. MicroRNAs were isolated 
from cells or paired cervical tissues by using the mirVana miRNA isolation kits (Applied 
Biosystems) following the manufacture’s protocol. 15ng mature miRNAs was used to 
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synthesis cDNA by Taqman MicroRNA Reverse Transcription kit (Applied Biosystems). 
The cDNA was diluted 10-fold and performed the quantitative RT-PCR using Taqman 
MicroRNA Assay kit (Applied Biosystems). Relative miRNA expression levels were 
calculated using rRNA U6 as an internal control.  
Xenografted tumor model in vivo. All animal experiments were performed according to 
protocols approved by the Institutional Animal Care and Use Committee. The female 
nude mice between 4 and 5 weeks were purchased from Beijing HFK Bioscience Co., Ltd. 
SiHa cells infected with lenti-virus constructs of LV10-NC or LV10-MiR-205 using 
Lipofectamine 2000 (invitrogen). SiHa stable lines (1×107) were transplanted 
subcutaneously into either side of flank of the same female nude mice. The tumor 
volumes were measured every week and calculated as length×width2×0.5. After 5 weeks 
after injection, the mice were anesthetized and killed. The tumor were carefully removed, 
photographed and weighed. The removed tumors were immediately stored in the liquid 
nitrogen. RNA and protein were isolated and subjected to the qPCR and western blotting 
assays.  
Wound healing assay. The 1×105 cells were seeded in 24 well plate and were incubated at 
37°C in 5% CO2 for 24 hours and subjected to serum starvation for additional 24 hours 
before making the wound. To avoid cell proliferation, cells were maintained in the serum 
free medium throughout of the experiment. An approximately 0.4-0.5 mm line was 
scraped using the fine end of sterile pipette tips. Then the plate was washed with 1×PBS 
for three times and cultured with serum-free medium for the indicated period of  time. 
The images were captured by inverted microscope. The images were then analyzed using 
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Image-J software.  
Transwell assay. 5×104 cancer cells were suspended in 150 μL serum-free medium added 
to the upper chamber and a total of  600 μL medium with 10％ serum was added to the 
bottom chamber as a chemoattractant. The 24-well Boyden chamber (8 μm; Corning, 
USA) were incubated at 37℃ for 48h. After wiped off  the non-migrating cells in the 
upper chamber attentively with cotton swabs, the cells on the polycarbonate membranes 
were fixed with 4％ paraformaldehyde and stained with 0.5％ crystal violet(Sigma, 
USA). The cells were counted in 5 random fields on each membrane. 
Immunofluorescence assay. Cells grown on cover slips in a 24 well plate were fixed in 
4% paraformaldehyde solution for 20 minutes after three washes in pre-warmed 1 × PBS. 
After another round of  washes in 1 × PBS, cells were permeabilised with 1% Triton 
X-100 solution on ice for 4 minutes. The permeabilisation solution was then removed by 
adding 1 × PBS, following which cells were blocked in 1% fish gelatin (G7765, 
Sigma-Aldrich) for 1 h. Incubation with the appropriate diluted primary antibody was 
performed over night at 4℃, followed by three washes in 1 × PBS for 5 minutes each. 
Antibodies used included anti-ASPP2 (Sigma-Aidrich, 1:100), anti-E-cadherin 
(Abcam,1:100) and anti-v5 (Serotec, 1:100). Cells were then incubated with the 
fluorescently labeled secondary antibody for 1 hour. Typically, these secondary antibodies 
were used at 1:400 dilutions in blocking solution. The secondaries were replaced with 1 × 
PBS and rinsed in H2O before being mounted by Mowiol onto slides. Images were 
captured by confocal microscopy.  
                                                                                                  21 
Statistical analysis. Data are expressed as the mean ± standard deviation (SED). 
Student’s t-test and one-way ANOVA analysis were performed to analysis the date using 
GraphPad software. Each experiment was performed at least three times. A value of  
P<0.05 was considered significant. 
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Figure Legends 
Figure 1. ASPP2 is a direct target of MiR-205. (a, b) Real-time RT-PCR and Western 
blotting (WB) analysis of ASPP2 at 72 hours post-transfection with either MiR-205 
mimics/negative controls (NC) mimics (a) or MiR-205 inhibitors/NC inhibitors (b). 
β-actin was used as loading controls in WB assays. (c) Real-time RT-PCR analysis of 
ASPP2 and MiR-205 expression in 6 cervical cancers and the paired normal controls. 
(d) The expression of MiR-205 and ASPP2 were displayed negative linear correlation 
in cervical cancers. (e) Schematic description of the hypothetical duplexes formed by 
the interactions between the binding site in the ASPP2 3’-UTR (top), 
MiR-205(middle) and the mutated ASPP2 3’-UTR (bottom). The seed recognition site 
is denoted. (f) All nucleotides of ASPP2 3’-UTR region that binds with MiR-205 are 
highly conserved across species as predicated by TargetScan 
(http://www.targetscan.org/vert_71/). (g) The luciferase activities of wild type or 
mutant 3’UTR ASPP2 luciferase reporter were measured after transfection with NC 
mimics or MiR-205 mimics. All histograms represent the mean ± SEM from three 
independent assays. *, P<0.05; **, P<0.01. 
 
Figure 2. Hypoxia-mediated ASPP2 suppression promotes EMT. (a) WB analysis of 
HIF-1a, ASPP2, E-cadherin and Vimentin expression under normoxia (N) and 
hypoxia (H) conditions. Protein expression as normalized to the loading control 
β-actin was quantified by Image J software. (b) Real-time RT-PCR analysis of ASPP2 
expression under normoxia (N) and hypoxia (H) conditions. Histograms represent the 
mean ± SEM from three independent assays. *, P<0.05. (c) Immunostaining analysis 
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of ASPP2/E-cadherin expression and localization under normoxia and hypoxia 
conditions. (d) WB analysis of ASPP2, E-cadherin and Vimentin after ectopic 
expression of ASPP2 under hypoxia conditions. (e) Immunostaining analysis of 
E-cadherin and exogenous ASPP2-v5 expression and localization under the conditions 
described in 2d. 
 
Figure 3. Hypoxia inhibits ASPP2 by the promoted MiR-205. (a) Real-time RT-PCR 
assay of MiR-205 under normoxia and hypoxia conditions. Histograms represent the 
mean ± SEM from three independent assays. *, P<0.05. (b) Linear correlation 
between decreased ASPP2 and increased MiR-205 was obtained in cancer cell lines 
(r2=0.9932, P<0.01). (c) WB analysis of HIF-1a and ASPP2 after ectopic expression of 
HIF-1a under normoxia conditions. β-actin was used as a loading control. (e,g) 
Real-time RT-PCR analysis of MiR-205 (e) and ASPP2 (g) under the conditions as 
described in 3c. (d) WB analysis of HIF-1a and ASPP2 after preventing 
hypoxia-induced HIF-1a by transfection with two independent RNAi specifically 
targeting HIF-1a (Si-HIF-1a 1 and 2). β-actin was used as a loading control. (f,h) and 
Real-time RT-PCR analysis of MiR-205 (f) and ASPP2 (h) under the conditions as 
described in 3d. (i) Immunostaining analysis of E-cadherin/ASPP2 expression and 
localization after transfection with NC mimic and MIR-205 mimics. (j) WB analysis 
of ASPP2, E-cadherin and Vimentin after transfection with negative control, MiR-205 
mimics or MiR-205 mimics+ASPP2 in HeLa, SiHa and A549 cells. (k) Real-time 
RT-PCR analysis of MiR-205 after transfection with NC inhibitors or MiR-205 
inhibitors under hypoxia conditions. (l) WB analysis of ASPP2, E-cadherin and 
Vimentin under the conditions as described in 3k. β-actin was used as a loading 
control. All histograms represent the mean ± SEM from three independent assays. *, 
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P<0.05; **, P<0.01. 
 
Figure 4. Inhibition ASPP2 promotes cell migration. (a) The efficiency of RNAi 
specifically targeting ASPP2 (Si-ASPP2) in comparison with scramble control (Scr) 
was confirmed by Western blotting (left). β-actin was used as a loading control. The 
bands were quantified using Image J software as normalized to β-actin (Right). (b) In 
vitro wound healing analysis of the cells transfected with either Scr or Si-ASPP2 cells. 
Representative photographs at different time points of 24 and 48 hours after making 
the wound were presented. (c) The plot represents the quantitative analysis of wound 
healing area from three independent experiments. Error bars, mean ± SEM (d) 
Migration rate was detected by a transwell assay in Scr and Si-ASPP2 cells. 
Representative photographs were presented. (e) The bar graph was the quantitative 
analysis of transwell assay. Error bars, mean ± SEM (n = 3 independent experiments). 
*, P<0.05, **, P<0.01. 
 
Figure 5. MiR-205-mediated ASPP2 suppression promotes cell migration. (a) WB 
analysis of ASPP2 after transfection cells with control, MiR-205 mimics and MiR-205 
mimic+ASPP2. β-actin was used as a loading control. (b) In vitro wound healing 
analysis in negative control, MiR-205 or MiR105+ASPP2 cells. Representative 
photographs at different time points after making the wound were presented. (c) 
Wound healing areas over time were quantified by using Image J. Error bars, mean ± 
SEM (n = 3 independent experiments). *, P<0.05; **, P<0.01, miR-205 vs NC; 
&,P<0.05,miR-205+ASPP2 vs NC; ##, P<0.01,miR-205+ASPP2 vs. miR-205 mimics 
(d) Migration rate was also detected by a transwell assay in negative control, MiR-205 
or MiR105+ASPP2 cells. Representative photographs were presented. (e) The bar 
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graph was the quantitative analysis of transwell assay. Error bars, mean ± SEM (n = 3 
independent experiments). *, P<0.05, **, P<0.01.  
 
Figure 6. MiR-205/ASPP2 axis promotes cell growth both in vitro and in vivo. (a) Cell 
proliferation was determined in triplicates at 24 hours intervals in the cells transfected 
with Scr or Si-ASPP2 by MTT assays. Error bars, mean ± SEM (n =3 independent 
experiments). *, P<0.05. (b) Cell proliferation was determined by a similar MTT assay 
as described in 6a in NC, MiR-205 mimics or MiR-205 mimic+ASPP2 transfected 
cells. Error bars, mean ± SEM (n = 3 independent experiments). *, P<0.05, miR-205 
vs. NC; &, P<0.05, miR-205+ASPP2 vs. NC; #, P<0.05, miR-205+ASPP2 vs. 
miR-205 mimics. (c) Tumor growth in nude mice subcutaneously injected into flanks 
with SiHa/DsRed control and SiHa/DsRed+MiR-205. Representative photographs of 
the tumors at different time after inoculation with either SiHa/DsRed control or 
SiHa/DsRed+MiR-205 cells (Right). Tumor volume was measure according to 
materials and methods. Data are presented as means ± SED (n = 5 per group) (left). *, 
P<0.05, **, P<0.01. (d) Photographs of the dissected tumors of either SiHa/DsRed 
control or SiHa/DsRed+MiR-205 cells (upper). Average of tumor weight was 
presented in the bar graph. Data are presented as means ± SED (n = 5 per group) 
(bottom). **, P<0.01. (e) Real-time analysis of MiR-205 and ASPP2 in the 
representative tumors. Histograms represent the mean ± SEM from three independent 
assays. **, P<0.01. (f) WB analysis of ASPP2, E-cadherin and Vimentin in the 
representative tumors. β-actin was used as a loading control.  
 
Figure 7. Proposed model of MiR-205 upregulation involved in promoting EMT 
process via targeting ASPP2. Under hypoxia conditions, HIF-1a is accumulated. 
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MiR-205 is subsequently increased, which then targets ASPP2 by interacting directly 
with the conserved 3’-UTR sites of ASPP2. ASPP2 expression is suppressed by 
MiR-205 and therefore confers to the promoted MT process via inhibiting E-cadherin. 
Meanwhile, MiR205/ASPP2 axis also contributes to the elevated cell proliferation in 
both cell types tested in this study, cervical and lung cancers. 
 
 







